38886655|t|Unveiling the therapeutic potential of IHMT-337 in glioma treatment: targeting the EZH2-SLC12A5 axis.
38886655|a|Glioma is the most common malignant tumor of the central nervous system, with EZH2 playing a crucial regulatory role. This study further explores the abnormal expression of EZH2 and its mechanisms in regulating glioma progression. Additionally, it was found that IHMT-337 can potentially be a therapeutic agent for glioma. The prognosis, expression, and localization of EZH2 were determined using bioinformatics, IHC staining, Western blot (WB) analysis, and immunofluorescence (IF) localization. The effects of EZH2 on cell function were assessed using CCK-8 assays, Transwell assays, and wound healing assays. Public databases and RT-qPCR were utilized to identify downstream targets. The mechanisms regulating these downstream targets were elucidated using MS-PCR and WB analysis. The efficacy of IHMT-337 was demonstrated through IC50 measurements, WB analysis, and RT-qPCR. The effects of IHMT-337 on glioma cells in vitro were evaluated using Transwell assays, EdU incorporation assays, and flow cytometry. The potential of IHMT-337 as a treatment for glioma was assessed using a blood-brain barrier (BBB) model and an orthotopic glioma model. Our research confirms significantly elevated EZH2 expression in gliomas, correlating with patient prognosis. EZH2 facilitates glioma proliferation, migration, and invasion alongside promoting SLC12A5 DNA methylation. By regulating SLC12A5 expression, EZH2 activates the WNK1-OSR1-NKCC1 pathway, enhancing its interaction with ERM to promote glioma migration. IHMT-337 targets EZH2 in vitro to inhibit WNK1 activation, thereby suppressing glioma cell migration. Additionally, it inhibits cell proliferation and arrests the cell cycle. IHMT-337 has the potential to cross the BBB and has successfully inhibited glioma progression in vivo. This study expands our understanding of the EZH2-SLC12A5 axis in gliomas, laying a new foundation for the clinical translation of IHMT-337 and offering new insights for precision glioma therapy.
38886655	39	47	IHMT-337	Chemical	-
38886655	51	57	glioma	Disease	MESH:D005910
38886655	83	87	EZH2	Gene	2146
38886655	88	95	SLC12A5	Gene	57468
38886655	102	108	Glioma	Disease	MESH:D005910
38886655	128	143	malignant tumor	Disease	MESH:D009369
38886655	180	184	EZH2	Gene	2146
38886655	275	279	EZH2	Gene	2146
38886655	313	319	glioma	Disease	MESH:D005910
38886655	365	373	IHMT-337	Chemical	-
38886655	417	423	glioma	Disease	MESH:D005910
38886655	472	476	EZH2	Gene	2146
38886655	614	618	EZH2	Gene	2146
38886655	902	910	IHMT-337	Chemical	-
38886655	996	1004	IHMT-337	Chemical	-
38886655	1008	1014	glioma	Disease	MESH:D005910
38886655	1069	1072	EdU	Chemical	MESH:C022811
38886655	1132	1140	IHMT-337	Chemical	-
38886655	1160	1166	glioma	Disease	MESH:D005910
38886655	1238	1244	glioma	Disease	MESH:D005910
38886655	1297	1301	EZH2	Gene	2146
38886655	1316	1323	gliomas	Disease	MESH:D005910
38886655	1342	1349	patient	Species	9606
38886655	1361	1365	EZH2	Gene	2146
38886655	1378	1384	glioma	Disease	MESH:D005910
38886655	1444	1451	SLC12A5	Gene	57468
38886655	1483	1490	SLC12A5	Gene	57468
38886655	1503	1507	EZH2	Gene	2146
38886655	1522	1526	WNK1	Gene	65125
38886655	1527	1531	OSR1	Gene	130497
38886655	1532	1537	NKCC1	Gene	6558
38886655	1593	1599	glioma	Disease	MESH:D005910
38886655	1628	1632	EZH2	Gene	2146
38886655	1653	1657	WNK1	Gene	65125
38886655	1690	1696	glioma	Disease	MESH:D005910
38886655	1786	1794	IHMT-337	Chemical	-
38886655	1861	1867	glioma	Disease	MESH:D005910
38886655	1933	1937	EZH2	Gene	2146
38886655	1938	1945	SLC12A5	Gene	57468
38886655	1954	1961	gliomas	Disease	MESH:D005910
38886655	2019	2027	IHMT-337	Chemical	-
38886655	2068	2074	glioma	Disease	MESH:D005910
38886655	Association	MESH:D005910	65125
38886655	Positive_Correlation	2146	6558
38886655	Association	MESH:D005910	57468
38886655	Association	MESH:D005910	6558
38886655	Association	65125	6558
38886655	Positive_Correlation	130497	2146
38886655	Positive_Correlation	2146	65125
38886655	Positive_Correlation	2146	57468
38886655	Association	MESH:D005910	2146
38886655	Association	MESH:D005910	130497

